Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

85.06USD
16 Aug 2019
Change (% chg)

$1.60 (+1.92%)
Prev Close
$83.46
Open
$84.64
Day's High
$85.36
Day's Low
$84.19
Volume
2,794,452
Avg. Vol
3,329,198
52-wk High
$87.07
52-wk Low
$66.10

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.57
Market Cap(Mil.): $212,382.41
Shares Outstanding(Mil.): 2,574.65
Dividend: 0.55
Yield (%): 2.67

Financials

  MRK.N Industry Sector
P/E (TTM): 24.92 29.73 33.85
EPS (TTM): 3.31 -- --
ROI: 13.08 13.04 12.69
ROE: 28.61 14.12 17.13

Breakingviews - The Exchange: Nile Rodgers and Merck Mercuriadis

LONDON (Reuters Breakingviews) - How much is a song worth? Two people who should know are the Chic founder and his manager, who have started a company to buy some of the world’s most famous back catalogues. They explain how music investing works and why many songwriters are miffed with Spotify.

13 Aug 2019

UPDATE 1-GSK ends development of Ebola vaccine, hands work to U.S. institute

LONDON, Aug 6 British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.

06 Aug 2019

Cancer drug Keytruda, vaccines propel Merck to quarterly profit beat

Merck & Co Inc reported better-than-expected second-quarter results on Tuesday and raised its full-year earnings forecast on strong demand for its blockbuster cancer immunotherapy Keytruda and vaccines.

30 Jul 2019

UPDATE 4-Cancer drug Keytruda, vaccines propel Merck to quarterly profit beat

July 30 Merck & Co Inc reported better-than-expected second-quarter results on Tuesday and raised its full-year earnings forecast on strong demand for its blockbuster cancer immunotherapy Keytruda and vaccines.

30 Jul 2019

Merck profit surges on strong sales of Keytruda, vaccines

July 30 U.S. drugmaker Merck & Co Inc reported a 56.4% rise in second-quarter profit on Tuesday, boosted by strong demand for its Keytruda immunotherapy, the dominant treatment for lung cancer, as well as higher sales of its vaccines.

30 Jul 2019

Bristol-Myers posts strong second quarter earnings as Eliquis, Orencia surprise

NEW YORK, July 25 Bristol-Myers Squibb, which is set to buy biotechnology company Celgene Corp soon for $74 billion, posted better-than-expected second-quarter earnings on Thursday on strong sales from its blood thinner Eliquis and rheumatoid arthritis treatment Orencia.

25 Jul 2019

Bayer sells Dr. Scholl's footcare brand to Yellow Wood Partners

FRANKFURT Germany's Bayer signed a deal on Monday to sell its Dr. Scholl's footcare brand to U.S. private investment firm Yellow Wood Partners for $585 million, the second of two consumer care products it had put on the block.

22 Jul 2019

Bayer sells Dr. Scholl's footcare brand to Yellow Wood Partners

FRANKFURT Germany's Bayer signed a deal on Monday to sell its Dr. Scholl's footcare brand to U.S. private investment firm Yellow Wood Partners for $585 million (£469.31 million), the second of two consumer care products it had put on the block.

22 Jul 2019

UPDATE 1-Bayer sells Dr. Scholl's footcare brand to Yellow Wood Partners

* U.S. buyer Yellow Wood to create stand-alone company (Adds background on strategic overhaul, share price rout)

22 Jul 2019

Merck's treatment for urinary, abdominal infections gets FDA approval

The U.S. Food and Drug Administration has approved Merck & Co Inc's combination treatment for complicated forms of urinary tract and abdominal infections, the drugmaker said on Wednesday.

17 Jul 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates